STAT3

Across TCGA pan-cancer cohorts, STAT3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STAT3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STAT3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STAT3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where STAT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	1.000	0.603	.006	34	view →
CCRCC	DFS	Tertile	All	0.543	0.881	.002	12	view →
PDAC	DFS	Tertile	II,III,IV	0.762	0.850	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

STAT3–LUAD (DFS)

Open the LUAD breakdown →